Mesenchymal Stem Cell-Mediated Oncolytic Virus Delivery for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as surgical resection, chemotherapy, and radiation therapy, are limited by invasiveness and collateral damage to healthy tissues, and oncolytic viruses have shown promise in laboratory settings but struggle to translate into improved clinical outcomes due to complex interactions with the tumor microenvironment and host immunity.
Innovation Solution
Modifying mesenchymal lineage precursor or stem cells to increase expression of Phosphatase and Tensin Homolog deleted on chromosome 10 alpha (PTENα) to enhance their ability to migrate to and kill tumor cells, and introducing a recombinant virus, like a herpes simplex virus (HSV) backbone, to deliver a therapeutic payload specifically to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (surgery, chemotherapy, radiation) are used, then tumor cells can be removed or killed, but healthy tissues suffer collateral damage and the treatments are invasive
Solution Approach 1:
The patent uses mesenchymal stem cells as intermediary carriers that naturally migrate to tumor sites and deliver oncolytic viruses. This mediator approach allows targeted delivery of therapeutic agents to cancer cells while avoiding direct exposure of healthy tissues to harsh treatments like chemotherapy and radiation, thereby reducing collateral damage while maintaining treatment effectiveness
Solution Approach 2:
The mesenchymal stem cells utilize their inherent biological property of autonomous migration toward tumor sites (tropism) to deliver the therapeutic payload. This self-directed navigation capability eliminates the need for external guidance systems or invasive administration methods, enabling precise targeting of cancer cells while sparing surrounding healthy tissues
2Object-affected harmful factors
If oncolytic viruses are used to treat cancer, then tumor cells can be selectively destroyed, but clinical outcomes remain limited due to complex interactions with tumor microenvironment and host immunity
Solution Approach 1:
The patent introduces mesenchymal stem cells as intermediaries that protect oncolytic viruses from premature degradation and immune detection in the circulation. These stem cell carriers shield the viral payload until it reaches the tumor microenvironment, where the viruses are released to selectively destroy cancer cells, thereby improving clinical outcomes by overcoming barriers in the tumor microenvironment and host immunity
Solution Approach 2:
The mesenchymal stem cells perform preliminary navigation and positioning functions by autonomously migrating to tumor sites before releasing the oncolytic viruses. This preliminary action ensures that the viruses are delivered directly to the target location, overcoming the complex barriers of the tumor microenvironment and maximizing their cytolytic effectiveness against cancer cells
3Reliability
If mesenchymal stem cells are modified to increase PTENα expression, then migration to and killing of tumor cells is enhanced, but cell modification complexity increases
Solution Approach 1:
The patent modifies a key biological parameter (PTENα expression level) in mesenchymal stem cells to enhance their anti-tumor efficacy. By overexpressing PTENα, the modified stem cells exhibit improved migration toward tumor cells and increased ability to kill cancer cells. This single parameter change approach simplifies the modification strategy compared to introducing multiple genetic elements or complex engineering approaches
4Object-affected harmful factors
If recombinant viruses are introduced to deliver therapeutic payload, then cancer cell infectivity increases, but delivery efficiency to tumor cells remains challenging
Solution Approach 1:
The patent uses mesenchymal stem cells as intermediary vehicles to deliver recombinant oncolytic viruses to tumor sites. These stem cell carriers protect the viruses during circulation and facilitate their targeted delivery to cancer cells through the stem cells' natural tropism for tumor tissue, thereby significantly improving delivery efficiency while maintaining high infectivity of the viral payload
Solution Approach 2:
The mesenchymal stem cells autonomously navigate to tumor sites and self-release the recombinant viruses directly at the target location. This self-service delivery mechanism eliminates the need for complex external delivery systems or invasive administration procedures, achieving high delivery efficiency through the inherent biological capabilities of the stem cell carriers
Data Source
AI summary
The present disclosure relates to cellular compositions that are modified to introduce a recombinant virus. Such compositions may be used to treat cancer by delivering vims to cancer cells.